20/20 is a diagnostics company deploying real-world data based machine learning algorithms to improve the accuracy and usefulness of blood tests. Our primary areas of focus are cancer detection and COVID-19 Testing.
OneTest™: A New AI Powered Multi-Cancer Blood Test & Machine Learning Algorithm for Broad Spectrum Early Cancer Detection
In 2019, we began to actively market in the U.S. and overseas an AI powered blood test for the early detection of multiple cancers called OneTest™. We saw substantial Quarterly revenue growth in the U.S.
As reported in a recent study by Cancers, a leading global peer-reviewed journal, this product is believed to be the world’s first cancer screening blood test powered by a machine learning algorithm built from data from tens of thousands of individuals screened yearly in a real-world clinical setting.
Blood testing to screen for many different cancers, though not yet widespread in the U.S., is very common throughout East Asia. Everyday millions of individuals in Japan, Korea, and China, and elsewhere in Asia visit “Health Check Centers” where they are tested with many of the same biomarkers that are part of OneTest. The foundation of our product is based on this East Asian testing paradigm, but our proprietary algorithms substantially improve the accuracy of standard biomarker testing by reducing the number of missed cancers by more than half.
CoronaCheck™: A Blood test for COVID-19 Antibodies
20/20 is offering FDA Authorized antibody lab test developed by Roche Diagnostics, and importing and distributing a rapid blood test for COVID-19 antibodies. During the one-month period since beginning promotion on March 18, we have sold over 70,000 tests generating over $1.2 million in revenue. We are now committed to integrating a digital reader with the lateral flow strip to enhance diagnostic accuracy and acquiring data to build a machine-learning algorithm to improve the usefulness of these test to determine who may relax social distancing with minimal risk.